U.S. Markets closed

IsoRay, Inc. (ISR)


NYSE MKT - NYSE MKT Delayed Price. Currency in USD
Add to watchlist
0.61+0.00 (+0.02%)
At close: 4:02PM EDT
People also watch
PBMDMNGARNNIBIOGALE
  • http://www.wkyt.com/content/news/Lexington-Cancer-doctor-unique-treatment-433645843.html

    Lexington cancer doctor saving women's lives
    For women with gynecologic cancer that comes back after radiation and surgery, it may be a new, lifesaving treatment. An oncologist at The Markey Cancer Center is attracting national attention with his new treatment.
    www.wkyt.com
  • KTOV = Mcap $16 Mil /Cash $17 Mil / ULTRA Low float / NDA submission for potential Blockbuster this Quarter = 20 BAGGER ..ONE OF THE BIGGEST BIOTECH OPPORTUNITY EVER ! Thank me later guys

    Kitov Pharma (KTOV)

    Market Cap: $17 M
    Cash $17 M
    Price: $1.50

    Shares Out: 10.6 Million

    Kitov Pharmaceuticals Initiates NDA Filing for KIT-302 as a Treatment for Osteoarthritis and Hypertension
    https://baystreet.ca/articles/research_reports/lifesci/Kitov062717.pdf

    Kitov Expects to Submit an NDA for KIT-302 in the Third Quarter 2017.Kitov announced that it began the process of compiling the documents necessary to file an NDA for its lead asset KIT-302 as a treatment for patients who experience both osteoarthritis and hypertension. The Company hired Parexel International Corporation, a clinical research organization, to digitalize and formally submit its NDA application. Kitov expects the filing to occur during the third quarter of 2017, with a potential FDA approval during the second quarter of 2018.

    KIT-302 is a combination drug that treats osteoarthritis pain and hypertension simultaneously

    Primary efficacy endpoint achieved Lead drug candidate KIT-302 achieved its primary efficacy endpoint in a pivotal Phase III trial

    Marketing potential Pipeline candidates address large, multi-billion dollar markets

    Products

    Kitov’s current pipeline products, KIT-301 and KIT-302, are combination drugs that treat OA pain and HTN simultaneously. In December 2015, KIT-302 successfully achieved the primary efficacy endpoint for its Phase III clinical trial. In August 2016, the United States Patent Office issued a patent covering KIT-302.
    Market

    Of the 27 million Americans with OA, 50% also suffer from HTN, which is also a common side effect of stand-alone OA drugs. With no single medication currently treating both conditions, KIT-301 and KIT-302 are targeting this multi-billion dollar market.

  • In light of John McCain's cancer diagnosis I don't understand why the ISR sales and marketing team are not on this. Not only can you help the guy out but at least get the word out in the news so others can find out about this technology.
  • Monster Microcaps Alert to ISR shareholders. Clean Energy Technologies (CETY) shares starting to move up. Cety opened their Europe Sales and Service Center for Europe sales and to serve 65 existing customers with CETY’s General Electric clean energy heat recovery systems and just announced they have already sold the first of hundreds of units to come.

    Each CETY Heat Recovery System sells for $300,000 and market demand is reported to several BILLION DOLLARS.

    CETY purchased Heat Recovery Systems in 2015 from General Electric and products are now very attractive to huge unmet markets and can achieve over $250 million annual sales within the next 2 years. Demand for conversion of wasted heat to electrical energy in big applications is VERY LARGE AND UNMET.

    Shares are steal with target of $.20 by year end and higher in 12 months.

    https://finance.yahoo.com/news/clean-energy-technologies-inc-secures-144700111.html

    Clean Energy Technologies, Inc. Secures New Order for Waste Biomass Application in Europe
    COSTA MESA, Calif., July 12, 2017 /PRNewswire/ -- Clean Energy Technologies, Inc. (CETY) announced today that its subsidiary Heat Recovery Solutions has secured a new Clean CycleTM generator order for a Waste Biomass application in Europe. Growing d
    finance.yahoo.com
  • Well it is moving..BUT WRONG WAY...Good investment IF THEY MAKE A PROFIT IN SEPT>>> If Not Down It Will GO...So Sad To See Investment Melt.!?!
  • ISR longs remember 3 yrs back when stock popped over 3$ ..lawsuits ensued for investors that got burned, right back to .55 it went
  • CHNR (PT: $3), GOOG (PT: $1000), ISRG (PT: $1000). These are my picks at the moment. Six month time frame.
  • That CEO has this quote -- ISORAY BOOM!
    https://www.twst.com/interview/interview-with-the-chairman-and-ceo-isoray-inc-nysemkt
    "IsoRay is very excited about our increasing ability to treat more aggressive and faster-growing cancers. Over the last five years, there have been numerous clinical activities going on in major institutions that have published very good results from the use of Cesium-131 in new therapy applications. The first series came out of Weill Cornell in New York City."

  • You all Missed your chance to sell this scam.
    Can't believe it's still trading
  • https://isoray.com/2017/06/the-wall-street-transcript/

    IsoRay CEO Thomas LaVoy Talks The Future Of Cesium-131 Brachytherapy With The Wall Street Transcript
    Insights into IsoRay's isotope used in brachytherapy, the patient experience, and the future of Cesium-131 in additional markets.
    isoray.com
  • Posted in $BDX conversation

    On Friday, there was a new Medical Devices report posted by The Wall Street Transcript. It has seven new long-form interviews with analysts and executives.

    In addition to $BDX, stocks discussed include $BCR, $MDT$, $ABT, $BAX, $EW, $BSX, $CAH, $VAR, $PTHN, $CTLT, $HRC, $STE, $IVC, $GB, $HYH, $TMO, $DHR, $WAT, $PKI, $A, $BTCY, $ISR, $TCMD, $EYES.

    http://bit.ly/2tnCO2r

  • Chairman and CEO of $ISR just gave an interview with The Wall Street Transcript. He addressed potential new investors directly :

    “I want the new potential investor to understand that we have made a major change in our business in the last year. We have assembled a very good executive team and have formulated a strong short-term and long-term strategic plan and growth strategy. We have totally revamped our sales force and have also looked at every part of our business including our production processes and the efficiency of every facet of our business.”

    Lots of excellent info in here.

    http://bit.ly/2tFEQug

    Interview with the Chairman and CEO: IsoRay, Inc. (NYSEMKT:ISR) - The Wall Street Transcript
    TWST: You became the CEO of IsoRay last February. Can I ask what attracted you to the position? Mr. LaVoy: I had been on the board since 2005, and had been the financial expert and the Audit Committee Chairman. I had also been with a number of other
    bit.ly
  • IGXT (MC $46 M)US-NDA Submission for BLOCKBUSTER Drug this month =1000%+ Upside Potential ! PLEASE READ THIS

    2 US-NDA submission within 2 months ,lot of Cash and heavily underpriced at a valuation of just $46 million .1 Big drug partnered with Endo Pharma already under review by FDA market launch expected in 1H 2018 .Load up guys before she the MEGA news hit the wire and thank me later .GL

    Intelgenx (IGXT)

    MarketCap $46 Million
    Cash ~$12 Million (including convertible debt) =cash untill 2021+
    Price: 0.70

    NDA submission for tadalafil (erectile dysfunction) thin-film version of Blockbuster drug Cialis in June or July
    NDA resubmission for Rizaport (migraine) in early Q3
    Partnership for Tadalafil in 2H 2017

    http://www.biotuesdays.com/features/2017/5/11/intelgenx-has-multi-faceted-bd-approach-for-its-oral-films

    IntelGenx previously confirmed the bioequivalence of Tadalafil to Eli Lilly’s Cialis, which had sales of $1.5-billion in 2016 but faces generic competition in 2020. IntelGenx has an exclusive license for oral films from Lilly for its dosing patent, which would allow Tadalafil to enter the ED market in the U.S. free from patent litigation from Lilly. Dr. Matzen explains that Tadalafil, which offers a discrete dosing alternative, could enter the market in 2018, with up to three years of market exclusivity before Cialis is hit with generic competition.

    Tadalafil is an erectile dysfunction (ED) treatment that boasts bioequivalence with Cialis, the current leading brand, and with a successful biostudy in-hand a 505(b)(2) NDA is set to be filed any day now, meaning that a full launch should be expected in mid-2018. Cialis is already winning-out over Viagra in terms of numbers of prescriptions, which is largely down to price and efficacy, but when Tadalafil comes to market with the same product in a more convenient and discreet delivery mechanism, IntelGenX should see a massive number of customers take-up its services.

    IntelGenx has multi-faceted BD approach for its oral films
    With a burgeoning pipeline of pharmaceutical oral films, IntelGenx’s (OTCQX:IGXT; TSXV:IGX) business development strategy is focused on partnering its product pipeline along with actively meeting with potential partners to explore manufacturing
    www.biotuesdays.com
  • More news, Not moving, One Day ISR will be HUGE! http://www.sciencedirect.com/science/article/pii/S0360301617307459

    Clinical Outcomes of Large Brain Metastases Treated with Neurosurgical Resection and Intraoperative Cesium-131 Brachytherapy: Results of a Prospective Trial
    www.sciencedirect.com
  • Lets Bring Back Babcock...
  • When is the Sales Team Going to Work..We don't hear much about Sales....Whats up ????????????...Not sales and no profit no stock...maybe do a little cutting for a bit and just that would help..??? remember for the share holders and future share holders and YES QUALITY PRODUCT TOO.........
  • I understood ISR saved a horse and some girl from peru.
  • I bought this POS at 60 cents.....should have known!
  • Stanford school of medicine using proteins to fight brain. ISR is not close to being mentioned
  • Research Alert to ISR shareholders

    Clean energy Technologies (CETY) is under a penny with a market cap of under $2 million and just announced the beginning of the adoption of their big ticket waste to energy systems to giant waste industry with adoption of 3 systems by Aries Clean Energy.

    CETY technology was purchased from General Electric and is attractive to huge unmet markets that can achieve over $250 million annual sales within the next 2 to 3 years.

    Shares could yield enormous percentage return on investment.

    https://www.thestreet.com/story/14139448/1/three-cety-clean-cycle-systems-commissioned-as-part-of-aries-clean-energys-waste-to-energy-facility.html

    Three CETY Clean Cycle™ Systems Commissioned As Part Of Aries Clean Energy's Waste-to-Energy Facility
    ...CETY
    www.thestreet.com